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Abstract
Background: The use of percutaneous needle biopsy in the evaluation of indeterminate renal
masses is controversial and its role in management remains largely unclear. We set to establish
current practice on this issue in UK urology departments.
Methods: We conducted a national questionnaire survey of all consultant urologists in the UK, to
establish current practice and attitudes towards percutaneous needle biopsy in the management of
indeterminate renal masses.
Results: 139 (43%) consultant urologists never use biopsy, whereas 111 (34%) always employ it
for the diagnosis of indeterminate renal masses. 75 (23%) urologists use biopsy only for a selected
patient group. Mass in a solitary kidney, bilateral renal masses and a past history of non-renal cancer
were the main indications for use of percutaneous biopsy. The risk of false negative results and
biopsy not changing the eventual management of their patients were the commonest reasons not
to perform biopsy.
Conclusion: There is a wide and varied practice amongst UK Consultant Urologists in the use of
percutaneous biopsy as part of the management of indeterminate renal masses. The majority of
urologists believe biopsy confers no benefit. However there is a need to clarify this issue in the
wake of recent published evidence as biopsy results may provide critical information for patients
with renal masses in a significant majority. It not only differentiates benign from malignant tissue
but can also help in deciding the management option for patients undergoing minimally invasive
treatments.
Background
Renal masses represent a variety of benign and malignant
neoplasms and generally the diagnosis is based on find-
ings at cross sectional imaging [1]. Advancement in the
resolution of diagnostic radiological modalities especially
computed tomography (CT) has not only led to better
characterization of these lesions but also caused a dra-
matic rise in the incidentally discovered renal masses.
Currently, more than one third of renal tumours are dis-
covered incidentally [2]. Despite these advances, it is not
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uncommon to see radiologists labeling a renal mass as
indeterminate in contemporary practice, especially small
lesions [3]. Management of this subgroup of patients, in
whom imaging is inconclusive, poses diagnostic and ther-
apeutic dilemmas. In addition, recently, minimally inva-
sive ablative methods such as radio frequency ablation
(RFA) and cryotherapy have shown great promise in the
treatment of small renal masses and it is well understood
that biopsy may provide the only chance to get a tissue
diagnosis in such cases. As there is controversy in the use
of needle biopsy in the evaluation of indeterminate renal
masses, we aimed to survey current practice in the United
Kingdom, amongst consultant urologists regarding this
issue.
Methods
A standardised questionnaire was sent to all UK consult-
ant urologists on the British Association of Urological Sur-
geons (BAUS) register in October 2005. The questionnaire
aimed to highlight individual practice regarding the use of
percutaneous needle biopsy in the management of inde-
terminate renal masses (Figure 1).
The participants were asked initially whether they used
needle biopsy in their practice and, if so, the indications
for its use along with their preferred imaging modality
employed to direct biopsy. If biopsy was not used, factors
precluding its use were established. Finally, perceptions,
in the form of general comments were also requested.
Recipients were asked to return the questionnaire in the
self-addressed, stamped reply envelope.
Results
Of the 525 questionnaires sent out, 336 (64%) were
returned, of which 11 were excluded because of incom-
plete answers. Hence, a total of 325 responses were there-
fore analysed.
139 (43%) consultant urologists never use biopsy,
whereas 111 (34%) always employ it for the diagnosis of
indeterminate renal masses. Moreover, 75 (23%) urolo-
gists answered both yes and no to the first question on the
questionnaire and mentioned that they use biopsy only
for a selected patient group. As shown in Table 1, mass in
the solitary kidney (57%), bilateral renal masses (51%),
and past history of non-renal cancer (46%) are the main
indications used by the participants who employ percuta-
neous biopsy in their practice. Medically unfit patients
with a renal mass, multidisciplinary team (MDT) decision
after inconclusive radiology and patients with possible
metastatic RCC are less common indications. Though not
asked in the questionnaire as a separate indication, 39
urologists described lymphoma as an indication.
Of the participants who do not use biopsy, 87% described
false negative results as the main reason, whereas 58%
believe that use of biopsy would not change the eventual
management of their patients (Table 2). Tumour seeding,
biopsy related complications, histopathological concerns,
false positive results and lack of available uro-radiologist
were other less common factors mentioned against the
biopsy.
Discussion
There is a great deal of controversy in the management of
patients found to have indeterminate renal masses [1,2,4].
Traditionally patients are either offered radical surgical
procedures or active surveillance, even though it is well
known that 20% of patients undergoing operation for a
suspicious renal mass will have a histopathologically
benign lesion [5].
Percutaneous needle biopsy has been an accepted diag-
nostic tool for solid intraabdominal masses, but its role
has largely remained unclear in the evaluation of solid
renal tumours. Our survey shows that currently only 34%
urologists use biopsy in their practice for renal tumours.
Biopsy can provide a definitive tissue diagnosis to direct
future therapy in patients with inoperable disease because
of locally advanced RCC and the presence of metastatic
disease and comorbidities [6]. Indications for biopsy in
contemporary urology though are expanding rapidly.
Some of the suggested indications in the recent literature
include small solid renal masses that do not fit the radio-
logical features of typical RCC and can form up to 50% of
suspicious renal masses [7]. Biopsy can be used to avoid
unnecessary surgery in these patients. On the other hand,
minimally invasive therapies such as Radio frequency
ablation (RFA) and cryotherapy are increasingly
employed in the management of small renal tumours
especially less than 4 cm [8]. Pre-operative percutaneous
needle biopsy may be the only opportunity to obtain a tis-
sue diagnosis [9].
This survey showed that the majority of UK urologists do
not use needle biopsy or use it only under special circum-
stances (66%). Their major concern is high false negative
results and especially the problem of managing a negative
biopsy. They also suggested that biopsy will not alter the
management of their patients. Although these concerns
are valid, many recent studies have shown that biopsy
may significantly alter the management of indeterminate
renal masses. Wood et al reported only 6% false negative
results in 79 biopsies and Neuzillet et al reported a false
negative result of 5.6% in 88 biopsies [10,11]. Not sur-
prisingly most of these false negative results were because
of insufficient tissue material. Clinical management was
altered due to biopsy in more than 40% of patients inBMC Urology 2007, 7:10 http://www.biomedcentral.com/1471-2490/7/10
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both studies. Bosniak classification for complex cysts is
not reliable and can lead to mismanagement [12]. Richter
et al assigned a definite diagnosis to 89.4% of patients
with Bosniak II and III cysts on the basis of CT guided
biopsy [13].
In addition, 24% of consultant urologists think that
pathologists have concerns against the use of this tech-
nique for categorisation of renal tumours into clinically
relevant histological categories that can influence the
management decisions. With the possibility of inconclu-
sive cytology, the diagnostic yield of aspiration cytology in
the evaluation of renal tumours is not considered to be
reliable [14]. Results can be improved by using core
biopsy in preference to fine needle aspiration cytology
[15] or a combination of both techniques [10]. This can
provide better architectural information about the tissue.
This technique can also provide tissue for additional his-
topathological and biochemical procedures. Lactate dehy-
drogenase (LDH) and protein assessment of the biopsy
specimens can be used to differentiate neoplastic from
inflammatory lesions [13]. In some cases distinction
between chromophobe RCC, oncocytoma and even clear
cell RCC (eosinophilic variant) can be problematic. [16]
Questionnaire Figure 1
Questionnaire.BMC Urology 2007, 7:10 http://www.biomedcentral.com/1471-2490/7/10
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Adult papillary renal tumors with oncocytic cells might be
a distinct variant in the papillary renal cell carcinoma
group. [17] Shah et al advised the use of Hale's colloidal
iron and contemporary immunohistochemical panel in
all such cases to define morphology [9]. According to
them all equivocal cases should undergo excision. By
adopting these strategies pathologists can play an impor-
tant role in the initial diagnosis and subsequent manage-
ment of indeterminate renal tumours.
In this survey, 42% of participants were concerned about
needle track seeding of tumour cells. This risk is increased
in patients with transitional cell carcinoma and probably
is more frequent with non-cutting needles than with cut-
ting needles [18]. In addition, most recent studies have
reported no such complication even after long follow-up
[10,11,13-15]. Richter et al have attributed this to the use
of a coaxial system, which shields the tissue outside
Gerota's fascia. [13]
Another concern regarding percutaneous biopsies has
been the potential for other complications such as bleed-
ing and haematoma (27%). This risk appears to be small
with fine needles than larger needles [19], and will only
require conservative management in the majority of cases.
Results can also be improved by performing biopsies only
in highly specialised uro-radiology centres by expert radi-
ologists. Helical CT guidance should be used in preference
to other modalities as it allows accuracy and fast image
acquisition [11].
Conclusion
Our survey shows a wide and varied practice amongst UK
Consultant Urologists in the management of indetermi-
nate renal masses and much of it is not evidence based.
The majority of urologists believe biopsy confers no ben-
efit. However there is a need to clarify this issue in the
wake of recent published evidence. Biopsy results may
provide critical information for patients with renal masses
in a significant majority. It not only differentiates benign
from malignant tissue but can also help in deciding the
management option for patients undergoing minimally
invasive treatments.
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